Value
7.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 9.5 |
| Fwd P/E | 3.4 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 32.9x
- ▸PEG: 0.05
- ▸Attractively valued
ALHC · Why this verdict
Why Alignment Healthcare (ALHC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Overall quality remains just below the minimum investment floor despite anomalously high cash conversion relative to net income; near-zero operating margins and the absence of a durable competitive advantage mean the business is not yet generating sustainable economics at scale. Quality breakdown | Quality should improve above the minimum floor, which requires the overall quality score to exceed 4.0 for 2 consecutive quarters — likely contingent on operating margins becoming meaningfully positive. | →Stable |
| CounterHigh-growth healthcare companies frequently operate at thin margins while prioritizing member growth; sustained 33% revenue expansion may drive operating leverage as fixed costs are spread across a larger revenue base. | ||
Revenue has expanded 33% year-over-year, reflecting strong membership or patient volume growth that places this company well above typical healthcare services sector growth rates; the expansion has supported 3 consecutive quarters of positive earnings surprises. Growth breakdown | Revenue growth should remain above 20% year-over-year for 2 consecutive quarters to confirm the trajectory is durable rather than a cyclical surge. | →Stable |
| CounterRevenue is substantially dependent on CMS government contracts, which means the growth rate is vulnerable to policy changes, reimbursement rate resets, or contract non-renewal that can interrupt the trajectory abruptly. | ||
Substantially all of the company's revenues depend on CMS government contracts, creating a single-counterparty concentration that exposes the business to abrupt revenue disruption if reimbursement parameters are changed or contracts are restructured. Bear case | If diversification proceeds, non-CMS revenue should grow to represent more than 20% of total within 12 months, reducing the binary policy risk. | →Stable |
| CounterMulti-year value-based care agreements with CMS can provide revenue visibility over extended horizons, partially mitigating the year-to-year renewal risk inherent in government-contract exposure. | ||
Short interest at 13% of float stands in sharp contrast to bullish analyst consensus with 26% upside to target; this creates a binary setup where fundamental confirmation could force a substantial short-covering rally, while any earnings or policy disappointment could accelerate selling from both shorts and longs. Key risks | Short interest should fall below 6% of float as fundamental delivery continues and the short thesis loses its supporting evidence. | →Stable |
| CounterThe 13% short interest may reflect informed institutional awareness of reimbursement risk and quality concerns that analyst price targets have not yet incorporated; the short position may be the better-informed side of the trade. | ||
Overall quality remains just below the minimum investment floor despite anomalously high cash conversion relative to net income; near-zero operating margins and the absence of a durable competitive advantage mean the business is not yet generating sustainable economics at scale.
→StableQuality breakdown
- Expectation
- Quality should improve above the minimum floor, which requires the overall quality score to exceed 4.0 for 2 consecutive quarters — likely contingent on operating margins becoming meaningfully positive.
CounterHigh-growth healthcare companies frequently operate at thin margins while prioritizing member growth; sustained 33% revenue expansion may drive operating leverage as fixed costs are spread across a larger revenue base.
Revenue has expanded 33% year-over-year, reflecting strong membership or patient volume growth that places this company well above typical healthcare services sector growth rates; the expansion has supported 3 consecutive quarters of positive earnings surprises.
→StableGrowth breakdown
- Expectation
- Revenue growth should remain above 20% year-over-year for 2 consecutive quarters to confirm the trajectory is durable rather than a cyclical surge.
CounterRevenue is substantially dependent on CMS government contracts, which means the growth rate is vulnerable to policy changes, reimbursement rate resets, or contract non-renewal that can interrupt the trajectory abruptly.
Substantially all of the company's revenues depend on CMS government contracts, creating a single-counterparty concentration that exposes the business to abrupt revenue disruption if reimbursement parameters are changed or contracts are restructured.
→StableBear case
- Expectation
- If diversification proceeds, non-CMS revenue should grow to represent more than 20% of total within 12 months, reducing the binary policy risk.
CounterMulti-year value-based care agreements with CMS can provide revenue visibility over extended horizons, partially mitigating the year-to-year renewal risk inherent in government-contract exposure.
Short interest at 13% of float stands in sharp contrast to bullish analyst consensus with 26% upside to target; this creates a binary setup where fundamental confirmation could force a substantial short-covering rally, while any earnings or policy disappointment could accelerate selling from both shorts and longs.
→StableKey risks
- Expectation
- Short interest should fall below 6% of float as fundamental delivery continues and the short thesis loses its supporting evidence.
CounterThe 13% short interest may reflect informed institutional awareness of reimbursement risk and quality concerns that analyst price targets have not yet incorporated; the short position may be the better-informed side of the trade.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Alignment Healthcare is growing revenues at 33% year-over-year with a strong analyst consensus (26% upside to target) and a favorable reward-to-risk ratio, but overall quality remains just below the minimum investment threshold — held back by near-zero operating margins and the complete absence of revenue diversification beyond government contracts; high short interest of 13% adds a binary volatility overlay to any catalyst.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.2 |
| ROA | 1.4 |
| Gross margin | 0.0 |
| Op margin | 0.5 |
| Net margin | 0.2 |
| Current ratio | 5.7 |
| FCF quality | 10.0 |
| Moat | 5.4 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 1000% FCF/NI
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 7/9
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 33% YoY
Momentum
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.6 |
- ▸Overbought (RSI 79)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.5 |
| Price target | 5.7 |
| erm sentiment | 5.0 |
Insider
3.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.3 |
| holder change | 5.1 |
- ▸Heavy insider selling — $26,609,821 (0.541% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.9 |
| quality rank | 5.5 |
| growth rank | 7.3 |
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.2 |
| support resistance | 0.5 |
| 52w position | 9.6 |
Risk (lower is worse)
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 6.5 |
| volatility | 2.2 |
| put call | 9.3 |
| implied vol | 0.0 |
| beta | 6.8 |
| debt equity | 3.8 |
- ▸High IV: 80%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:7.1>=5.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-0.6=NEGATIVE
- INSIDER:0.54%=HEAVY
Warning (0)
none
Reward-to-Risk
-0.59
Upside
-8.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 27d with 3/4 beat streak
SuitabilityAggressive — MCap $4.9B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.6=NEGATIVE.
The strongest dimensions are Growth at 10.0, Catalyst at 7.5, and Value at 7.3; the weakest are Insider at 3.1, Quality at 3.9, and Technical at 4.1. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of -0.59 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Accelerating Revenue Growth
Trip ifRevenue growth falls below 15% year-over-year for 2 consecutive quarters.
- P2Quality Below Floor Thin Margins
Trip ifOverall quality score rises above 4.0 for 2 consecutive quarters, indicating the quality floor has been cleared.
- P3Cms Contract Concentration Risk
Trip ifNon-CMS revenue grows above 20% of total revenue for 2 consecutive quarters.
- P4High Short Interest Binary Setup
Trip ifShort interest falls below 6% of float.